GSK acquired global rights to Brexafemme, a novel antifungal from Scynexis that is approved for treating vaginal yeast infections. The deal also gives GSK the chance to commercialize the drug in other indications.
Organon’s proposed acquisition of Forendo Pharma is the company’s third since spinning out of Merck in the summer. Clinical-stage Forendo is developing a new, potentially more targeted approach to treating endometriosis.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The FDA has approved Brexafemme, a Scynexis antifungal drug, for treating vaginal yeast infections. The drug is the biotech’s first FDA-approved product and it also represents the first new antifungal drug class in 20 years.
Apprentice, a Jersey City, New Jersey-based startup, has raised $2.5 million from Silverton Partners and Hemi Ventures to improve its augmented reality solution.
GE leads a $10 million round in a company that intends to make the management of hospital clinical and non-clinical capital equipment headache free and mobile enabled.
Late Friday, MT Pharma America broke the news that the FDA had approved its experimental amyotrophic lateral sclerosis (ALS) drug Radicava, the second-ever drug approved for ALS and the first in over 20 years.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.